deltatrials
Completed PHASE3 NCT00036309

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Sponsor: Eli Lilly and Company

Conditions Depressive Disorder
Interventions Duloxetine Hydrochloride
Updated 5 times since 2017 Last updated: Jul 18, 2006 Started: May 31, 2002 Completion: Jul 31, 2003

This PHASE3 trial investigates Depressive Disorder and is currently completed. Eli Lilly and Company leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States